Ernexa Therapeutics (NASDAQ:ERNA) Trading Down 15.4% – Here’s What Happened

Ernexa Therapeutics Inc. (NASDAQ:ERNA)’s share price fell 15.4% during trading on Monday . The stock traded as low as $5.33 and last traded at $5.43. Approximately 248,372 shares changed hands during trading, a decline of 82% from the average daily volume of 1,359,927 shares. The stock had previously closed at $6.42.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on ERNA. Brookline Capital Markets initiated coverage on Ernexa Therapeutics in a report on Thursday, May 7th. They set a “buy” rating and a $30.00 price target for the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Ernexa Therapeutics in a research note on Tuesday, April 21st. Wall Street Zen upgraded shares of Ernexa Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, June 27th. Finally, Zacks Research upgraded shares of Ernexa Therapeutics to a “hold” rating in a research report on Monday, May 11th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $30.00.

Ernexa Therapeutics Stock Performance

The company has a market capitalization of $6.35 million, a PE ratio of -0.21 and a beta of 2.50. The firm’s 50-day simple moving average is $8.05 and its 200 day simple moving average is $11.37.

Ernexa Therapeutics (NASDAQ:ERNA) last announced its quarterly earnings results on Monday, May 11th. The company reported ($6.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.95) by ($5.00). As a group, equities analysts anticipate that Ernexa Therapeutics Inc. will post -18.02 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Ernexa Therapeutics stock. Susquehanna International Group LLP purchased a new position in shares of Ernexa Therapeutics Inc. (NASDAQ:ERNA) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 30,854 shares of the company’s stock, valued at approximately $34,000. Susquehanna International Group LLP owned approximately 0.39% of Ernexa Therapeutics at the end of the most recent reporting period. 70.55% of the stock is owned by institutional investors and hedge funds.

About Ernexa Therapeutics

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.